Russia has announced that its experimental Cancer Vaccine, Enteromix, has successfully completed preclinical trials, giving new hope in the fight against cancer.
Veronika Skvortsova, head of the Russian Federal Medical-Biological Agency (FMBA), shared the update at the Eastern Economic Forum in Vladivostok. She said years of research, including three years of preclinical testing, showed strong results and proved the vaccine’s readiness for the next stage, pending official approval.
The trials demonstrated a tumour reduction of 60 to 80 percent depending on the cancer type. Researchers also reported improved survival rates among test subjects.
The first focus of the Cancer Vaccine is colorectal cancer, which remains one of the most common and deadly cancers worldwide. Scientists are also developing versions of Enteromix to target glioblastoma, an aggressive brain cancer, and melanomas, including rare ocular melanoma.
Some media outlets reported that the vaccine showed 100 percent effectiveness, though these claims have not been independently confirmed. International observers, including Newsweek, noted they could not verify such figures.
For now, the FMBA has not set a timeline for human trials or global availability. However, Skvortsova’s statement suggested that Russia could soon seek regulatory approval.
The news has attracted worldwide attention, as experts continue to look for breakthroughs that can change cancer treatment. While the new Cancer Vaccine is not yet proven in humans, the results so far are encouraging.
If successful in further trials, Enteromix could represent a major step forward in oncology, offering hope to patients and families around the world who are waiting for more effective treatment options.
In other related news also read New Cancer Drug Doubles Patient Survival Time
